Physician profile
Elliot Groff
NPI 1508328345
$2,053.87
in general payments reported to CMS, 2019-2025
25 companies · $845 in 2025
The $845 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.40 · 2023: $413 · 2024: $780 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $280.56 | 2023 | Myrisk |
| Exeltis, USA INC. | $273.19 | 2024-2025 | Slynd |
| Mayne Pharma Commercial LLC | $172.78 | 2025 | |
| Hologic Sales and Service, LLC | $170.63 | 2023-2025 | Aptima, Acessa Provu System |
| Shield Therapeutics INC | $143.48 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $125.95 | 2023-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $113.78 | 2023-2025 | Phexxi, Solosec, Phexx |
| Novo Nordisk INC | $102.08 | 2025 | Wegovy |
| Dexcom, INC. | $93.48 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $89.85 | 2024-2025 | Nexplanon |
| Pfizer INC. | $81.09 | 2024-2025 | |
| Astellas Pharma US INC | $71.50 | 2025 | Veozah |
| Abbvie INC. | $48.46 | 2025 | |
| Lilly USA, LLC | $43.60 | 2024 | Zepbound |
| Biogen, INC. | $36.07 | 2025 | Zurzuvae |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $34.30 | 2024-2025 | Paragard T 380a, Summit Doppler |
| Sumitomo Pharma America, INC. | $24.70 | 2024 | Myfembree |
| Aspira Women'S Health INC | $24.28 | 2024 | Ova1 |
| Innovation Technologies INC | $23.63 | 2025 | Irrisept |
| Viiv Healthcare Company | $20.15 | 2025 | Apretude |
| Millicent US INC | $19.50 | 2023 | Intrarosa |
| Minerva Surgical, INC | $17.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.40 | 2022 | |
| Glaxosmithkline, LLC. | $14.48 | 2024 | Bexsero |
| Currax Pharmaceuticals LLC | $12.85 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Groff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.